聚焦肥胖合并糖尿病患者 礼来口服新药探索体重管理新路径

Group 1 - The global prevalence of diabetes is rising, with China's adult diabetes rate reaching 11.9%, primarily consisting of type 2 diabetes patients, many of whom are also overweight or obese [1] - Weight loss of over 10% significantly increases the remission rate of type 2 diabetes, but traditional methods like diet and exercise often yield limited long-term results for these patients [1] - The 2024 expert consensus on weight management for diabetes patients emphasizes the importance of using weight-beneficial glucose-lowering medications, particularly recommending GLP-1 receptor agonists with strong weight loss effects [1] Group 2 - Eli Lilly's ATTAIN-2 clinical trial results show that the oral small molecule drug orforglipron leads to significant weight loss (average of 10.5% or 10.4 kg) and a reduction in A1C levels by 1.8% among overweight or obese participants with type 2 diabetes [2] - 75% of participants achieved A1C levels ≤6.5%, indicating a substantial health benefit, including reduced cardiovascular risk, while maintaining safety comparable to existing GLP-1 drugs [2] - The convenience of orforglipron, which does not require dietary restrictions, represents a breakthrough in weight management for patients, aligning with China's health planning goals [2] Group 3 - Eli Lilly expresses confidence that orforglipron will enhance accessibility to obesity treatment globally and reshape the treatment landscape [3] - The drug is the first oral small molecule non-peptide GLP-1 receptor agonist, offering a flexible alternative to current injectable treatments, which is expected to meet diverse patient needs [3] - Eli Lilly plans to submit a market application for obesity treatment to global regulatory authorities, aiming to integrate effective weight management into national health strategies [3]